Adverse events
Erenumab and galcanezumab appear to have a favourable safety profile.
Approximately, 37% of the patients treated with each CGRP MoAb suffered
a drug-related adverse event (Table 1 ). In fact, only 1
(1,20%) patient treated with erenumab and 1 receiving galcanezumab
(1,79%) had to stop the treatment due to paresthesia and toxicodermia,
respectively.